WO2013026989A3 - Liposome comprenant au moins un derive de cholesterol - Google Patents

Liposome comprenant au moins un derive de cholesterol Download PDF

Info

Publication number
WO2013026989A3
WO2013026989A3 PCT/FR2012/051924 FR2012051924W WO2013026989A3 WO 2013026989 A3 WO2013026989 A3 WO 2013026989A3 FR 2012051924 W FR2012051924 W FR 2012051924W WO 2013026989 A3 WO2013026989 A3 WO 2013026989A3
Authority
WO
WIPO (PCT)
Prior art keywords
cholesterol derivative
liposome
liposomes
relates
cholesterol
Prior art date
Application number
PCT/FR2012/051924
Other languages
English (en)
Other versions
WO2013026989A2 (fr
Inventor
Corinne Chaimbault
Magali MICHAUD
Patrick Berna
Sophie SCHALLER
Firas BASSISSI
Simon Eastman
Original Assignee
Trophos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trophos filed Critical Trophos
Priority to CN201280041297.5A priority Critical patent/CN103764122A/zh
Priority to JP2014526535A priority patent/JP6162699B2/ja
Priority to CA2845691A priority patent/CA2845691A1/fr
Priority to BR112014004163A priority patent/BR112014004163A2/pt
Priority to EP12758576.8A priority patent/EP2747750A2/fr
Priority to US14/240,990 priority patent/US20150056269A1/en
Priority to MX2014002228A priority patent/MX2014002228A/es
Publication of WO2013026989A2 publication Critical patent/WO2013026989A2/fr
Priority to AU2013203682A priority patent/AU2013203682B2/en
Publication of WO2013026989A3 publication Critical patent/WO2013026989A3/fr
Priority to US15/184,122 priority patent/US20160339041A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une nouvelle forme galénique de dérivé de cholestérol. Plus particulièrement l'invention concerne des liposomes comprenant au moins un dérivé de cholestérol et des compositions comprenant lesdits liposomes.
PCT/FR2012/051924 2011-08-25 2012-08-22 Liposome comprenant au moins un derive de cholesterol WO2013026989A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CN201280041297.5A CN103764122A (zh) 2011-08-25 2012-08-22 包含至少一种胆甾醇衍生物的脂质体
JP2014526535A JP6162699B2 (ja) 2011-08-25 2012-08-22 少なくとも１つのコレステロール誘導体を含むリポソーム
CA2845691A CA2845691A1 (fr) 2011-08-25 2012-08-22 Liposome comprenant au moins un derive de cholesterol
BR112014004163A BR112014004163A2 (pt) 2011-08-25 2012-08-22 lipossoma, composição, uso de pelo menos um composto de fórmula (i) e uso dos lipossomas
EP12758576.8A EP2747750A2 (fr) 2011-08-25 2012-08-22 Liposome comprenant au moins un derive de cholesterol
US14/240,990 US20150056269A1 (en) 2011-08-25 2012-08-22 Liposome comprising at least one cholesterol derivative
MX2014002228A MX2014002228A (es) 2011-08-25 2012-08-22 Liposoma que contiene al menos un derivado de colesterol.
AU2013203682A AU2013203682B2 (en) 2011-08-25 2013-04-11 Liposome comprising at least one cholesterol derivative
US15/184,122 US20160339041A1 (en) 2011-08-25 2016-06-16 Liposome comprising at least one cholesterol derivative

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR1102594A FR2979239A1 (fr) 2011-08-25 2011-08-25 Liposome comprenant au moins un derive de cholesterol
FR1102594 2011-08-25
FR1102862A FR2979240A1 (fr) 2011-08-25 2011-09-21 Liposome comprenant au moins un derive de cholesterol
FR1102862 2011-09-21

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US14/240,990 A-371-Of-International US20150056269A1 (en) 2011-08-25 2012-08-22 Liposome comprising at least one cholesterol derivative
AU2013203682A Division AU2013203682B2 (en) 2011-08-25 2013-04-11 Liposome comprising at least one cholesterol derivative
US15/184,122 Division US20160339041A1 (en) 2011-08-25 2016-06-16 Liposome comprising at least one cholesterol derivative

Publications (2)

Publication Number Publication Date
WO2013026989A2 WO2013026989A2 (fr) 2013-02-28
WO2013026989A3 true WO2013026989A3 (fr) 2013-08-08

Family

ID=45422200

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2012/051924 WO2013026989A2 (fr) 2011-08-25 2012-08-22 Liposome comprenant au moins un derive de cholesterol

Country Status (9)

Country Link
US (2) US20150056269A1 (fr)
EP (1) EP2747750A2 (fr)
JP (2) JP6162699B2 (fr)
CN (1) CN103764122A (fr)
BR (1) BR112014004163A2 (fr)
CA (1) CA2845691A1 (fr)
FR (2) FR2979239A1 (fr)
MX (1) MX2014002228A (fr)
WO (1) WO2013026989A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3740211A4 (fr) * 2018-01-18 2021-04-14 Endoprotech, Inc Traitement d'un dysfonctionnement microvasculaire

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2013087A (en) * 1978-01-27 1979-08-08 Sandoz Ltd Sterol liposomes containing medicaments
FR2650181A1 (fr) * 1989-07-27 1991-02-01 Stallergenes Lab Procede pour combiner un melange de substances heterogenes a des liposomes
WO1999013816A2 (fr) * 1997-09-16 1999-03-25 Nexstar Pharmaceuticals, Inc. Compositions a base de liposomes renfermant de la camptothecine
US6143321A (en) * 1997-02-06 2000-11-07 Duke University Liposomes containing active agents
WO2004082581A2 (fr) * 2003-03-11 2004-09-30 Trophos Application a titre de medicaments de derives de cholest-4-en-3- one, compositions pharmaceutiques les renfermant et nouveaux derives
WO2006027454A1 (fr) * 2004-09-07 2006-03-16 Trophos Nouveaux derives du 3,5-seco-4-nor-cholestane et leurs utilisations
WO2007080270A2 (fr) * 2005-12-20 2007-07-19 Trophos Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation
WO2007101925A1 (fr) * 2006-03-09 2007-09-13 Trophos Utilisation de derives du 3,5-seco-4-nor-cholestane pour l'obtention d'un medicament cytoprotecteur
WO2007118967A1 (fr) * 2006-03-31 2007-10-25 Trophos Utilisation de derives du cholest-4-en-3-one pour l'obtention d'un medicament cytoprotecteur
WO2008077248A1 (fr) * 2006-12-22 2008-07-03 Miv Therapeutics Inc. Revêtements pour des dispositifs médicaux implantables pour une administration de liposomes
WO2008142231A2 (fr) * 2007-03-28 2008-11-27 Trophos Nouvelle composition à base d'oxime de cholest-4-èn-3-one
WO2009044010A2 (fr) * 2007-07-25 2009-04-09 Trophos Utilisation d'au moins un dérivé oxime de la cholest-4-èn-3-one comme antioxydants
WO2009044011A2 (fr) * 2007-07-25 2009-04-09 Trophos Utilisation d'au moins un dérivé oxime du 3,5-seco-4-nor-cholestane comme antioxydants
WO2009092892A2 (fr) * 2007-10-30 2009-07-30 Trophos Nouvelle composition pour traiter les effets secondaires des traitements anticancereux
WO2010012904A2 (fr) * 2008-07-30 2010-02-04 Trophos Nouveaux dérivés de l'oxime de cholest-4-èn-3-one, compositions pharmaceutiques les renfermant, et procédé de préparation
CN101642431A (zh) * 2009-08-28 2010-02-10 海南永田药物研究院有限公司 奥扎格雷钠脂质体注射剂
WO2010076418A1 (fr) * 2008-12-29 2010-07-08 Trophos Nouveaux dérivés d'oxime du 3,5-seco-4-nor-cholestane, compositions pharmaceutiques les renfermant, et procédé de préparation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975282A (en) * 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
DE3542773A1 (de) * 1985-12-04 1987-06-11 Roehm Pharma Gmbh Hautwirksame pharmaka mit liposomen als wirkstofftraeger
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE4432378A1 (de) * 1994-09-12 1996-03-14 Bayer Ag Injizierbare liposomale Arzneizubereitungen
EP0801557B1 (fr) * 1995-10-12 2003-07-02 Supergen, Inc. Formulation de liposomes contenant des 5beta steroides
GB0111279D0 (en) * 2001-05-10 2001-06-27 Nycomed Imaging As Radiolabelled liposomes
AR031744A1 (es) * 2001-11-08 2003-10-01 Paoli Tomas De Proliposomas en polvo, un procedimiento para la elaboracion de dichas proliposomas en polvo, procedimiento para la preparacion de una composicion farmaceutica empleando proliposomas en polvo y aparato para ser empleado en el procedimiento de elaboracion de dichas proliposomas en polvo
US20060110441A1 (en) * 2004-10-28 2006-05-25 Harry Wong Lyophilized liposome formulations and method
CA2631243A1 (fr) * 2005-12-08 2007-06-14 Wyeth Compositions liposomales
PL1975486T3 (pl) 2007-03-28 2015-05-29 Fillon Tech Sas Societe Par Actions Simplifiee Zawór dozujący
CN102459291B (zh) * 2009-04-27 2015-11-25 Mcw研究基金会股份有限公司 神经保护性化合物和它们的应用
EP2531175A2 (fr) * 2010-02-01 2012-12-12 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Liposomes comprenant des médicaments amphipathiques et procédé pour leur préparation

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2013087A (en) * 1978-01-27 1979-08-08 Sandoz Ltd Sterol liposomes containing medicaments
FR2650181A1 (fr) * 1989-07-27 1991-02-01 Stallergenes Lab Procede pour combiner un melange de substances heterogenes a des liposomes
US6143321A (en) * 1997-02-06 2000-11-07 Duke University Liposomes containing active agents
WO1999013816A2 (fr) * 1997-09-16 1999-03-25 Nexstar Pharmaceuticals, Inc. Compositions a base de liposomes renfermant de la camptothecine
WO2004082581A2 (fr) * 2003-03-11 2004-09-30 Trophos Application a titre de medicaments de derives de cholest-4-en-3- one, compositions pharmaceutiques les renfermant et nouveaux derives
WO2006027454A1 (fr) * 2004-09-07 2006-03-16 Trophos Nouveaux derives du 3,5-seco-4-nor-cholestane et leurs utilisations
WO2007080270A2 (fr) * 2005-12-20 2007-07-19 Trophos Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation
WO2007101925A1 (fr) * 2006-03-09 2007-09-13 Trophos Utilisation de derives du 3,5-seco-4-nor-cholestane pour l'obtention d'un medicament cytoprotecteur
WO2007118967A1 (fr) * 2006-03-31 2007-10-25 Trophos Utilisation de derives du cholest-4-en-3-one pour l'obtention d'un medicament cytoprotecteur
WO2008077248A1 (fr) * 2006-12-22 2008-07-03 Miv Therapeutics Inc. Revêtements pour des dispositifs médicaux implantables pour une administration de liposomes
WO2008142231A2 (fr) * 2007-03-28 2008-11-27 Trophos Nouvelle composition à base d'oxime de cholest-4-èn-3-one
WO2009044010A2 (fr) * 2007-07-25 2009-04-09 Trophos Utilisation d'au moins un dérivé oxime de la cholest-4-èn-3-one comme antioxydants
WO2009044011A2 (fr) * 2007-07-25 2009-04-09 Trophos Utilisation d'au moins un dérivé oxime du 3,5-seco-4-nor-cholestane comme antioxydants
WO2009092892A2 (fr) * 2007-10-30 2009-07-30 Trophos Nouvelle composition pour traiter les effets secondaires des traitements anticancereux
WO2010012904A2 (fr) * 2008-07-30 2010-02-04 Trophos Nouveaux dérivés de l'oxime de cholest-4-èn-3-one, compositions pharmaceutiques les renfermant, et procédé de préparation
WO2010076418A1 (fr) * 2008-12-29 2010-07-08 Trophos Nouveaux dérivés d'oxime du 3,5-seco-4-nor-cholestane, compositions pharmaceutiques les renfermant, et procédé de préparation
CN101642431A (zh) * 2009-08-28 2010-02-10 海南永田药物研究院有限公司 奥扎格雷钠脂质体注射剂

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 201018, Derwent World Patents Index; AN 2010-C10744, XP002672816 *
DEMEL R A ET AL: "Structural requirements of sterols for the interaction with lecithin at the air-water interface", BIOCHIMICA ET BIOPHYSICA ACTA. BIOMEMBRANES, AMSTERDAM, NL, vol. 255, no. 1, 17 January 1972 (1972-01-17), pages 311 - 320, XP023350899, ISSN: 0005-2736, [retrieved on 19720117], DOI: 10.1016/0005-2736(72)90030-2 *
DEMEL R A ET AL: "The effect of sterol structure on the permeability of lipomes to glucose, glycerol and Rb<+>", BIOCHIMICA ET BIOPHYSICA ACTA. BIOMEMBRANES, AMSTERDAM, NL, vol. 255, no. 1, 17 January 1972 (1972-01-17), pages 321 - 330, XP023350900, ISSN: 0005-2736, [retrieved on 19720117], DOI: 10.1016/0005-2736(72)90031-4 *
MAERKER, G. ET AL: "A-ring oxidation products from .gamma.-irradiation of cholesterol in liposomes", JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY , 70(3), 255-9 CODEN: JAOCA7; ISSN: 0003-021X, vol. 70, no. 3, 1993 - 1993, pages 255 - 259, XP009166580 *
MARTIN LEE J: "Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis.", IDRUGS : THE INVESTIGATIONAL DRUGS JOURNAL AUG 2010, vol. 13, no. 8, August 2010 (2010-08-01), pages 568 - 580, XP007921500, ISSN: 2040-3410 *
NAKAGAWA Y ET AL: "Transfer of steroids and alpha-tocopherol between liposomal membranes.", JOURNAL OF BIOCHEMISTRY FEB 1980 LNKD- PUBMED:6892636, vol. 87, no. 2, February 1980 (1980-02-01), pages 497 - 502, XP002686453, ISSN: 0021-924X *
RAMSAMMY L S ET AL: "Association of cholestanol and cholestanone with lysophosphatidylcholine", CHEMISTRY AND PHYSICS OF LIPIDS, LIMERICK, IR, vol. 34, no. 2, 1 February 1984 (1984-02-01), pages 127 - 138, XP025198071, ISSN: 0009-3084, [retrieved on 19840201], DOI: 10.1016/0009-3084(84)90038-0 *
SCHALLER SOPHIE ET AL: "TRO40303, a New Cardioprotective Compound, Inhibits Mitochondrial Permeability Transition", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 333, no. 3, June 2010 (2010-06-01), pages 696 - 706 URL, XP007920460, ISSN: 0022-3565 *

Also Published As

Publication number Publication date
BR112014004163A2 (pt) 2017-03-14
JP2017122119A (ja) 2017-07-13
JP6162699B2 (ja) 2017-07-12
CN103764122A (zh) 2014-04-30
FR2979240A1 (fr) 2013-03-01
JP2014524460A (ja) 2014-09-22
EP2747750A2 (fr) 2014-07-02
US20150056269A1 (en) 2015-02-26
CA2845691A1 (fr) 2013-02-28
US20160339041A1 (en) 2016-11-24
FR2979239A1 (fr) 2013-03-01
WO2013026989A2 (fr) 2013-02-28
MX2014002228A (es) 2014-05-28

Similar Documents

Publication Publication Date Title
WO2012042371A3 (fr) Composition pharmaceutique
WO2012061607A3 (fr) Compositions comprenant des nanostructures fonctionnalisées à base de carbone et procédés associés
WO2013177419A3 (fr) Compositions de nanoparticules lipidiques ainsi que procédés de fabrication et procédés d&#39;utilisation de celles-ci
WO2011138281A3 (fr) Procédé de production de dithiine-tétracarboxy-diimides
WO2011098582A3 (fr) Nouvelles formes de chlorhydrate d&#39;ivabradine
WO2012138981A3 (fr) Nouveaux intermédiaires et procédés pour la préparation du ticagrelor
EP2620651A4 (fr) Compresseur centrifuge
WO2013034979A3 (fr) Formes cristallines du cabazitaxel
WO2012101011A3 (fr) Nouveaux dérivés d&#39;arylbenzocycloalkylamides
WO2012162414A3 (fr) Stabilisateur de col de chemise
WO2013092673A3 (fr) Nouvelle combinaison
WO2013048177A3 (fr) Composé aromatique condensé avec un sélénophène et son procédé de production
AP2012006232A0 (en) New association between 4-ä3-ÄCIS-hexahydrocyclopentaÄcÜpyrrol-2(1H)-YLÜpropoxyübenzamide and an Acetylcholinesterase inhibitor, and pharmaceutical compositions containing it.
EP2679824A4 (fr) Compresseur
WO2011058525A3 (fr) Procédé de synthèse de la forme a du chlorhydrate d&#39;erlotinib et de la forme b du chlorhydrate d&#39;erlotinib
WO2010015656A3 (fr) Nouveaux alcoxypyrazoles
WO2013155338A8 (fr) Benzamides substituées et leurs utilisations
WO2012154879A3 (fr) Inhibiteurs d&#39;autophagie
WO2013053354A3 (fr) Pièce coulée
WO2012080176A3 (fr) Compositions pharmaceutiques
EP2539999A4 (fr) Résonateur micromécanique amélioré
WO2011029516A3 (fr) Composition cosmétique à action antimicrobienne
WO2013092672A3 (fr) Procédé pour la production recombinante de labyrinthopeptines et dérivés fonctionnels de celles-ci
WO2014064712A3 (fr) Procédé amélioré pour la préparation de fulvestrant
WO2013026989A3 (fr) Liposome comprenant au moins un derive de cholesterol

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12758576

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2845691

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2014526535

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/002228

Country of ref document: MX

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014004163

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 14240990

Country of ref document: US

ENP Entry into the national phase

Ref document number: 112014004163

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140221